0
0
Published: February 9, 2026
For decades, the medical community has relied on general risk calculators to guess who might suffer a second heart attack or stroke. But for the millions of adults living with both obesity and established heart disease—yet without diabetes—those calculators have often been imprecise.
A landmark study published in Pharmacoeconomics on January 19, 2026, has changed the landscape. Researchers leveraging data from the massive SELECT clinical trial have developed the first validated “risk equations” specifically designed for this population. These mathematical models allow doctors and health economists to predict secondary cardiovascular events with unprecedented accuracy, while also accounting for the protective effects of modern treatments like semaglutide.
The Need for Precision in Secondary Prevention
When a patient already has cardiovascular disease (CVD), the goal shifts from “primary prevention” (preventing the first event) to “secondary prevention” (preventing the next one). However, obesity adds a layer of biological complexity that standard models often fail to capture.
“We have reached a point in medicine where ‘one size fits all’ no longer suffices,” says Dr. Elena Rossi, a cardiologist not involved in the study. “For patients with a high BMI and existing heart issues, the trajectory of their health is influenced by specific variables—like smoking history and previous minor strokes—that need to be weighted differently than in the general population.”
The researchers utilized data from the SELECT trial, a multicenter, double-blind study that followed over 17,000 adults aged 45 and older. Every participant had a body mass index (BMI) of at least 27 kg/m² and a history of heart attack, stroke, or peripheral arterial disease, but none had diabetes at the start of the study.
Breaking Down the Data: Who Is at Risk?
The study population reflected a high-risk demographic: a mean age of 61.6 years, predominantly male (72.3%), and a heavy history of tobacco use (over 65% were current or former smokers).
Over the course of the follow-up period, the trial recorded 789 acute coronary syndrome (ACS) events—which include heart attacks and unstable angina—and 338 strokes. By analyzing these events against patient histories, the researchers identified the most lethal predictors.
The Strongest Predictors of Future Events
The equations revealed that specific past medical incidents are “red flags” for future complications:
-
For Stroke: A history of atrial fibrillation (an irregular heart rhythm) and Transient Ischemic Attack (TIA), often called a “mini-stroke,” were the most significant indicators. A prior TIA increased the hazard ratio for a full stroke by 1.70, making it the strongest predictor in the model.
-
For Acute Coronary Syndrome (ACS): A baseline history of ACS (76.4% of the group) remained a primary driver for future cardiac episodes.
The “Semaglutide Factor”
Perhaps the most significant addition to these new equations is the inclusion of semaglutide (the active ingredient in medications like Wegovy) as a “treatment covariate.”
The SELECT trial previously made headlines by showing that semaglutide reduces the risk of major heart problems. This new analysis quantifies that impact within the risk model:
-
ACS Reduction: Treatment with semaglutide was associated with a 23% reduction in the hazard for heart-related events.
-
Stroke Reduction: The drug showed a 10% reduction in the hazard for stroke.
By including the medication in the math, health economists can now more accurately model the long-term cost-effectiveness of prescribing these GLP-1 receptor agonists to high-risk patients.
Why This Matters for Public Health
For the average patient, these equations might seem like “back-end” math, but the real-world implications are profound.
-
Tailored Treatment: Doctors can use these insights to identify which patients require the most aggressive intervention. For example, a patient with obesity and a prior TIA is now clearly flagged as “ultra-high risk” for a major stroke.
-
Insurance and Access: Health economic modeling is what insurance companies and national health services use to decide which drugs to cover. By proving the long-term value and risk-reduction of semaglutide in this specific group, these equations provide the evidence needed to expand patient access to life-saving treatments.
-
Personalized Health Decisions: Knowing that semaglutide offers a 23% hazard reduction for heart attacks provides a concrete “number” that can help patients and doctors weigh the benefits of starting a new medication.
A Balanced View: Limitations of the Study
While the study is a breakthrough, experts urge a cautious interpretation. The equations were derived from a clinical trial population, which is often more “controlled” than the general public.
“Clinical trial participants usually have better adherence to medication and more frequent follow-ups than the average person,” notes Dr. Rossi. “While these equations are a massive step forward, we must see how they perform in ‘real-world’ clinical settings where lifestyle factors are more variable.”
Additionally, the study focused on a four-year time horizon. While the predictive performance was “good” for that window, cardiovascular disease is a lifelong battle, and longer-term data will be needed to see if these equations hold up over a decade or more.
Moving Forward
The validation of these risk equations marks a shift toward precision cardiometabolic medicine. By acknowledging that obesity and heart disease interact in unique ways, the medical community is moving away from guesswork and toward data-driven certainty.
For readers living with overweight or obesity and a history of heart issues, this study is a reminder of the importance of proactive management. The “math” of your health is changing, and for many, the odds are finally starting to look better.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Study Citation:
Bøg, M., Bojesen, A. B., Emerson, S., et al. (2026). Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial. Pharmacoeconomics. doi:10.1007/s40273-025-01580-2
